Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- TOPICS／Prof. Yamanaka's iPS Cell Preparation Method Patented in Japan
September 29, 2008
- Drugs Will Continue to Be a Core Business of New Meiji Company
September 29, 2008
- Number of Centenarians Up to 36,276
September 29, 2008
- 75% of People Dissatisfied with Current Social Security System
September 29, 2008
- REGULATORY NEWS IN BRIEF
September 29, 2008
- Gardasil Reduces Patients' Burden: Merck
September 29, 2008
- Korosho to Actively Hire Ex-Employees of Pharma Companies
September 29, 2008
- Blood Donations Falling Sharply among Young People
September 29, 2008
- PhRMA to Present Comments on Draft GL for Biosimilars Announced by Korosho
September 29, 2008
- Number of Lifestyle Disease-Free Persons Increases for First Time
September 29, 2008
- Draft GL Announced for Approval of Biosimilars
September 29, 2008
- Measles Vaccination Rates Remain Under 40% in Teenagers: Korosho Survey
September 29, 2008
- BUSINESS NEWS IN BRIEF
September 29, 2008
- Long-term Hospitalization for Schizophrenia Causes Problems in IADL
September 29, 2008
- DTP Focused on at 2008 IFPW General Membership Meeting
September 29, 2008
- Many Physicians Lack Accurate Knowledge about Medicinal Narcotics
September 29, 2008
- Pure Pharma Business Model Approaching the End: Mr K. Masuzoe
September 29, 2008
- Avastin Effective in Patients with or without K-ras Gene Mutation
September 29, 2008
- Quintiles to Provide Lab Data Directly Comparable with Those from Other Countries
September 29, 2008
- Mylan to Increase Number of MRs to 300, Open 4 More Offices
September 29, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…